Food Allergy Fund Drug Repurposing Program Grant

The Food Allergy Fund is the leading nonprofit dedicated to funding food allergy research. FAF's grants support the creation of new treatments that will address the root causes of food allergies.
Grants will be awarded to research teams that propose innovative approaches to repurposing therapeutics for the prevention or treatment of food allergy. We would welcome proposals identifying either an existing FDA-approved drug or drug in development with human safety data that has a rationale for the prevention of food allergies, prevention or treatment of food induced anaphylaxis, or an improved method for maintaining food allergic tolerance in previously allergic patients.
Examples could involve drugs such as enzyme inhibitors or immunomodulators with specific activities that lend themselves to alter intestinal, mucosal or immune function.

Eligibility

Eligibility and Submission Criteria
Proposals will be reviewed and scored based on innovation and collaboration (across disciplines and/or institutions).Teams should have adequate pharmaceutical expertise or microbiome, genetic and human clinical trial expertise to document an eventual developmental approach for human use.The letter of intent is limited to two pages outlining the approach and rationale involved in the studies. A third page identifying the team involved is also required.An estimate of the potential budget is also requested. Overall budgets should be appropriate for the scope of work proposed.The top scoring proposals will be requested to submit a 10-page proposal with a fully documented budget and evidence of institutional approval.Grants will be reviewed by the Food Allergy Fund’s Scientific Advisory Board.Grant indirect costs are capped at 10%.Suggested annual funding tiers are $75,000, $150,000, and $250,000. Requests outside these tiers will be considered on a case-by-case basis.Grants may be awarded for terms of one or two years.This RFP is open to academic investigators, university spinouts, and early-stage companies.